CA1090703A - Thiobenzamides - Google Patents
ThiobenzamidesInfo
- Publication number
- CA1090703A CA1090703A CA350,653A CA350653A CA1090703A CA 1090703 A CA1090703 A CA 1090703A CA 350653 A CA350653 A CA 350653A CA 1090703 A CA1090703 A CA 1090703A
- Authority
- CA
- Canada
- Prior art keywords
- thiobenzamide
- chloro
- morpholinoethyl
- pharmaceutically acceptable
- pharmaceutical preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Abstract Pharmaceutical preparations are disclosed which contain p-chloro-N-(2-morpholinoethyl)thiobenzamide or a pharmaceutically acceptable acid addi-tion salt thereof. The active ingredient exhibits monoamineoxidase inhibiting activity.
Description
)'703 The present invention relates to pharmaceutical preparations having monoamineoxidase inhibiting activity and containing p-chloro-N-(2-morpholino-ethyl)-thiobenzamide.
In accordance with the present invention it has been found that p-chloro-N-(2-morpholinoethyl)-thiobenzamide of the formula CQ ~ C - NH - CH - CH - N ~ (I) and acid addition salts thereof possess monoamineoxidase (MAO) inhibiting activity.
The present invention is accordingly concerned with pharmaceutical preparations having MAO inhibiting activity, said preparations containing as essential active ingredient p-chloro-N-~2-morpholinoethyl)-thiobenzamide or a pharmaceutically acceptable acid addition salt thereof.
The p-chloro-N-(2-morpholinoethyl)-thiobenzamide is a known compound which is described in French Patent Specification No. 1,501,846.
As mentioned earlier, p-chloro-N-~2-morpholinoethyl)-thiobenzamide and its acid addition salts possess monoamineoxidase ~YAO) inhibiting activity.
On the basis of this activity, p-chloro-N-(2-morpholinoethyl)-thiobenzamide and its pharmaceutically acceptable acid addition salts can be used for the treatment of depressive conditions.
The MAO inhibiting activity of p-chloro-N-~2-morpholinoethyl)-thiobenzamide can be demonstrated using standard methods. Thus, p-chloro-N-~2-morpholinoethyl)-thiobenzamide was administered p.o. to rats. 1 hour after the administration, the rats were killed and the MAO inhibiting activity in the liver homogenates was measured according to the method described in Biochem.
Pharmacol. 12 ~1963) 1439-1441. The thus-ascertained activity of p-chloro-N-~, :~ .
, .
`:
,: ~:: ,, ' ` ' . ':
,, :
(2-morpholinoethyl)thiobenzamide as well as its toxicity is evident from the following ED50 value ~mol/kg, p.o. in the rat) and LD50 value ~mg/kg, p.o.
in the mouse):
Thiobenzamlde ED50 LD50 . - .
p-Chloro-N-(2-morpholinoethyl)-thiobenzamide 1250-2500 p-Chloro-N-~2-morpholinoethyl)-thiobenzamide and its pharmaceutical-ly acceptable aci~ addition salts can be used as medicaments; for example, in the form of pharmaceutical preparations which contain them in association with a pharmaceutically acceptable carrier material. This carrier material can be an organic or inorganic inert carrier material which is suitable for enteral ~e.g. oral) or parenteral administration such as, for example, water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, poly-alkyleneglycols and the like. The pharmaceutical preparations can be made up in solid form (e.g. as tablets, dragees, suppositories or capsules) or in liquid form (e.g. as solutions, suspensions or emulsions). The pharmaceutical preparations may be sterilised and/or may contain adjuvants such as preserving, stabilising, wetting or emulsifying agents, salts for variation of the osmotic pressure or buffers. The pharmaceutical preparations may also contain other therapeutically valuable materials.
Convenient pharmaceutical dosage forms contain from ca 1 mg to 100 mg of p-chloro-N-(2-morpholinoethyl)-thiobenzamide or of a pharmaceutically acceptable acid addition salt thereof. Convenient oral dosage ranges lie at about 0.1 mg/kg per day to about 5 mg/kg per day. Convenient parenteral dos-age ranges lie at about 0.01 mg/kg per day to about 0.5 mg/kg per day. It will be appreciated that the aforementioned ranges can be increased or decreas-ed according to individual requirements and the directions of the attending ~'t - 2 -._ ,, .
',', ': ~ - . . ' : - , . , - ' ' , ' ' .,. .,' ' ' " ' ' ' ' ' ' ' i . ' ' ' .. . '' ~090 ~(~3 physician. Oral administration is preferred.
The following Example illustrates the present invention Example Tablets containing the following ingredients are manufactured in a manner known per se:
p-Chloro-N-(2-morpholinoethyl~-thiobenzamide 50.0 mg Lactose 95.0 mg Maize starch 100.0 mg Talc 4.5 mg Magnesium stearate 0.5 mg Weight of one tablet 250.0 mg ~, . .:: . -: . . . . . . . . .
In accordance with the present invention it has been found that p-chloro-N-(2-morpholinoethyl)-thiobenzamide of the formula CQ ~ C - NH - CH - CH - N ~ (I) and acid addition salts thereof possess monoamineoxidase (MAO) inhibiting activity.
The present invention is accordingly concerned with pharmaceutical preparations having MAO inhibiting activity, said preparations containing as essential active ingredient p-chloro-N-~2-morpholinoethyl)-thiobenzamide or a pharmaceutically acceptable acid addition salt thereof.
The p-chloro-N-(2-morpholinoethyl)-thiobenzamide is a known compound which is described in French Patent Specification No. 1,501,846.
As mentioned earlier, p-chloro-N-~2-morpholinoethyl)-thiobenzamide and its acid addition salts possess monoamineoxidase ~YAO) inhibiting activity.
On the basis of this activity, p-chloro-N-(2-morpholinoethyl)-thiobenzamide and its pharmaceutically acceptable acid addition salts can be used for the treatment of depressive conditions.
The MAO inhibiting activity of p-chloro-N-~2-morpholinoethyl)-thiobenzamide can be demonstrated using standard methods. Thus, p-chloro-N-~2-morpholinoethyl)-thiobenzamide was administered p.o. to rats. 1 hour after the administration, the rats were killed and the MAO inhibiting activity in the liver homogenates was measured according to the method described in Biochem.
Pharmacol. 12 ~1963) 1439-1441. The thus-ascertained activity of p-chloro-N-~, :~ .
, .
`:
,: ~:: ,, ' ` ' . ':
,, :
(2-morpholinoethyl)thiobenzamide as well as its toxicity is evident from the following ED50 value ~mol/kg, p.o. in the rat) and LD50 value ~mg/kg, p.o.
in the mouse):
Thiobenzamlde ED50 LD50 . - .
p-Chloro-N-(2-morpholinoethyl)-thiobenzamide 1250-2500 p-Chloro-N-~2-morpholinoethyl)-thiobenzamide and its pharmaceutical-ly acceptable aci~ addition salts can be used as medicaments; for example, in the form of pharmaceutical preparations which contain them in association with a pharmaceutically acceptable carrier material. This carrier material can be an organic or inorganic inert carrier material which is suitable for enteral ~e.g. oral) or parenteral administration such as, for example, water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, poly-alkyleneglycols and the like. The pharmaceutical preparations can be made up in solid form (e.g. as tablets, dragees, suppositories or capsules) or in liquid form (e.g. as solutions, suspensions or emulsions). The pharmaceutical preparations may be sterilised and/or may contain adjuvants such as preserving, stabilising, wetting or emulsifying agents, salts for variation of the osmotic pressure or buffers. The pharmaceutical preparations may also contain other therapeutically valuable materials.
Convenient pharmaceutical dosage forms contain from ca 1 mg to 100 mg of p-chloro-N-(2-morpholinoethyl)-thiobenzamide or of a pharmaceutically acceptable acid addition salt thereof. Convenient oral dosage ranges lie at about 0.1 mg/kg per day to about 5 mg/kg per day. Convenient parenteral dos-age ranges lie at about 0.01 mg/kg per day to about 0.5 mg/kg per day. It will be appreciated that the aforementioned ranges can be increased or decreas-ed according to individual requirements and the directions of the attending ~'t - 2 -._ ,, .
',', ': ~ - . . ' : - , . , - ' ' , ' ' .,. .,' ' ' " ' ' ' ' ' ' ' i . ' ' ' .. . '' ~090 ~(~3 physician. Oral administration is preferred.
The following Example illustrates the present invention Example Tablets containing the following ingredients are manufactured in a manner known per se:
p-Chloro-N-(2-morpholinoethyl~-thiobenzamide 50.0 mg Lactose 95.0 mg Maize starch 100.0 mg Talc 4.5 mg Magnesium stearate 0.5 mg Weight of one tablet 250.0 mg ~, . .:: . -: . . . . . . . . .
Claims
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A pharmaceutical preparation which contains as essential active ingredient p-chloro-N-(2-morpholinoethyl)-thiobenzamide or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA350,653A CA1090703A (en) | 1976-03-08 | 1980-04-25 | Thiobenzamides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA1674/76 | 1976-03-08 | ||
AT167476A AT344713B (en) | 1976-03-08 | 1976-03-08 | METHOD FOR PRODUCING NEW MORPHOLINE DERIVATIVES AND THEIR ACID ADDITION SALTS |
CA273,220A CA1081227A (en) | 1976-03-08 | 1977-03-04 | Thiobenzamides |
CA350,653A CA1090703A (en) | 1976-03-08 | 1980-04-25 | Thiobenzamides |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1090703A true CA1090703A (en) | 1980-12-02 |
Family
ID=27147768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA350,653A Expired CA1090703A (en) | 1976-03-08 | 1980-04-25 | Thiobenzamides |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA1090703A (en) |
-
1980
- 1980-04-25 CA CA350,653A patent/CA1090703A/en not_active Expired
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5175185A (en) | Naphthalene derivatives and processes of preparation thereof | |
IE45256L (en) | Quinazolone derivatives | |
NO137500B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF 2-AMINO-2`, 6`-PROPION-XYLIDIDE FOR USE AS A MEDICINE FOR HEART ARRYTHMIA | |
CA1069441A (en) | Pharmaceutical composition containing 2,1,3-benzothiazole | |
CA1090703A (en) | Thiobenzamides | |
IL43820A (en) | Pharmaceutical compositions for treatment of spastically disabled human beings containing bronchodilating sympathomimetic amines | |
US4083950A (en) | Stable acetylsalicylic acid and phenylpropanolamine salt composition | |
IE821108L (en) | Pyrazoline derivatives. | |
US4430338A (en) | Method of treatment patients at risk of sudden death | |
Hikino et al. | Pharmacological actions of analogues of feruloylhistamine, an imidazole alkaloid of ephedra roots1 | |
ES8100249A1 (en) | Novel hydroxamic acid compounds, method for preparation thereof and medicaments containing such compounds | |
US4122177A (en) | Method of treating oligospermia and asthenospermia | |
IE780921L (en) | 1-acyl-2-hydroxy-1,3-diamino-propanes. | |
US3885045A (en) | Therapeutic composition containing 1-(2-hydroxy-2-indanyl)-propylamine | |
JPS56115715A (en) | Physiologically active agent containing (3- dimethylcarbam-oxyphenyl) trimethyl ammonium derivative | |
US3968145A (en) | Methyl 2(1 chloronaphth-2-yloxy)propionate | |
JPS6289672A (en) | Drug containing p-chloro-n-(2-morpholinoethyl) thiobenzamide | |
US3934009A (en) | Agents for lowering the lipid level in plasma | |
ES8304923A1 (en) | New peptide, process for preparation thereof and pharmaceutical composition containing it. | |
JPS5675428A (en) | Hypoglycemic agent containing procainamide hydrochloride | |
IL41564A (en) | Pharmaceutical compositions containing n-cyclohexylbenzylamine derivatives | |
GB8608893D0 (en) | D-nor-7-ergoline derivatives | |
ES481792A1 (en) | N1-Benzoyl-N2-phenyl-1,3-diaminopropane-2-ols and their salts, process for their preparation and medicaments containing them. | |
JPS5697268A (en) | Lower alkanoic acid derivative, salt and preparation thereof and preventing agent and remedy for diabetic complication containing the same as active constituent | |
US4556664A (en) | Method and composition for the treatment of cardiac arrhythmias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |